| __timestamp | Alnylam Pharmaceuticals, Inc. | AstraZeneca PLC |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 5579000000 |
| Thursday, January 1, 2015 | 276495000 | 5997000000 |
| Friday, January 1, 2016 | 382392000 | 5890000000 |
| Sunday, January 1, 2017 | 390635000 | 5757000000 |
| Monday, January 1, 2018 | 505420000 | 5932000000 |
| Tuesday, January 1, 2019 | 655114000 | 5958000000 |
| Wednesday, January 1, 2020 | 654819000 | 5991000000 |
| Friday, January 1, 2021 | 792156000 | 9736000000 |
| Saturday, January 1, 2022 | 883015000 | 9762000000 |
| Sunday, January 1, 2023 | 1004415000 | 10935000000 |
| Monday, January 1, 2024 | 1126232000 | 13583000000 |
Data in motion
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, AstraZeneca PLC and Alnylam Pharmaceuticals, Inc. have demonstrated contrasting yet intriguing R&D investment strategies. From 2014 to 2023, AstraZeneca's R&D expenses have consistently dwarfed those of Alnylam, with AstraZeneca investing nearly 10 times more in 2023 alone. However, Alnylam has shown a remarkable growth trajectory, increasing its R&D spending by over 400% during the same period. This surge reflects Alnylam's aggressive push into pioneering RNA interference therapies. Meanwhile, AstraZeneca's steady investment underscores its strategy of maintaining a robust pipeline across various therapeutic areas. As the pharmaceutical industry continues to innovate, these spending patterns offer a glimpse into the strategic priorities of two leading players.
Novo Nordisk A/S or AstraZeneca PLC: Who Invests More in Innovation?
Johnson & Johnson vs AstraZeneca PLC: Strategic Focus on R&D Spending
Research and Development Investment: AstraZeneca PLC vs Teva Pharmaceutical Industries Limited
Analyzing R&D Budgets: AstraZeneca PLC vs BeiGene, Ltd.
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Ascendis Pharma A/S
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and United Therapeutics Corporation
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Incyte Corporation
Research and Development: Comparing Key Metrics for Alnylam Pharmaceuticals, Inc. and Exelixis, Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Opthea Limited
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Amneal Pharmaceuticals, Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Xencor, Inc.